Presence of antiphospholipid antibodies as a risk factor for thrombotic events in patients with connective tissue diseases and idiopathic thrombocytopenic purpura

Internal Medicine

Volumn 55, Issue 6, 2016, Pages 589-595

  Habe, Koji ^a   Owada, Hide ^a   Matsumoto, Takeshi ^a   Ohishi, Kohshi ^a   Ikejiri, Makoto ^b   Matsubara, Kimiko ^a   Morioka, Tatsuhiko ^a   Kamimoto, Yuki ^a   Ikeda, Tomoaki ^a   Katayama, Naoyuki ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

APS; LA; SLE; Thrombosis; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; BIOLOGICAL MARKER;

ABORTION; ARTERY THROMBOSIS; ARTICLE; BUDD CHIARI SYNDROME; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PREGNANCY COMPLICATION; PREMATURITY; RETROSPECTIVE STUDY; RISK FACTOR; SHUNT THROMBOSIS; SKIN ULCER; SPINAL CORD INFARCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD; COMPLICATION; IMMUNOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREVALENCE; VENOUS THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOMARKERS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREVALENCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84960950512     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5536     Document Type: Article

References (45)

1. Palomo IG, Segovia FM, Alarcon ML, et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci 12: 3093-3103, 2007.
2. Staub HL, Bertolaccini ML, Munther MA. Antiphosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 52: 804-810, 2012.
3. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 19: 406-411, 2010.
4. Hughes G. Hughes Syndrome: the antiphospholipid syndrome-a clinical overview. Clin Rev Allergy Immunol 32: 3-12, 2007.
5. Chandramouli NB, Rodgers GM. Management of thrombosis in women with antiphospholipid syndrome. Clin Obstet Gynecol 44: 36-47, 2001.
6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 376: 1498-1509, 2010.
7. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol 87: S75-S81, 2012.
8. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome; major clinical and serological features. Medicine 68: 366-374, 1989.
9. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 68: 353-365, 1989.
10. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 16: 627-633, 2007.
11. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 14: 499-504, 2005.
12. Tubach F, Hayem G, Marchand JL, et al. IgG anti-beta2- glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 27: 1437-1443, 2000.
13. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study. Thromb Haemost 66: 520-524, 1991.
14. Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol 10: 289-293, 1991.
15. Gupta R, Thabah MM, Gupta S, Shankar S, Kumar A. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int 30: 277-279, 2009.
16. Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158: 141-144, 2008.
17. Pasoto SG, Chakkour HP, Natalino RR, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clin Rheumatol 31: 1331-1338, 2012.
18. Unikiene D, Misiu-niene N. Antiphospholipid syndrome in patients with systemic connective tissue diseases. Medicina (Kaunas) 39: 454-459, 2003.
19. Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep 8: 100-108, 2006.
20. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 90: 108-115, 2003.
21. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile:a multicenter prospective study. Blood 118: 4714-4718, 2011.
22. Habe K, Wada H, Matsumoto T, et al. Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. Int J Hematol 97: 345-350, 2013.
23. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 8: 586-595, 1999.
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590, 1980.
25. Rasmussen A, Ice JA, Li H, et al. Comparison of the American- European Consensus Group Sjögren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 73: 31-38, 2014.
26. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guide devel oped by explicit methods for the American Society of Hematology. Blood 88: 3-40, 1996.
27. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86: 1327-1330, 2001.
28. Kaburaki J, Kuwana M, Ikeda Y. Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med 37: 796, 1998.
29. Muñoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29: 182-190, 1999.
30. Fujieda Y, Atsumi T, Amengual O, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21: 1506-1514, 2012.
31. Zhou H, Fu R, Wang H, et al. Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Ann Hematol 92: 79-87, 2013.
32. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome:a systemtic review of the literature. Blood 101: 1827-1832, 2003.
33. Ghosh K, Shetty S, Mohanty D. Detection of unexpected lupus anticoagulant during preparation of normal pooled plasma (NPP) from healthy volunteers. Thromb Haemost 84: 519-521, 2000.
34. Gris JC, Perneger TV, Quéré I, et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 102: 3504-3513, 2003.
35. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 84: 4203-4208, 1994.
36. Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/ SSC lupus anticoagulant testing guidelines: how far have hese been adopted by laboratories? J Thromb Haemost 9: 2117-2119, 2011.
37. Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's viper venom time and dilute kaolin clotting time detect different populations of anti bodies in patients with the "antiphospholipid" syndrome. Thromb Haemost 80: 250-257, 1998.
38. Pengo V, Denas G, Bison E, et al; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of antiprothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res 126: 150-153, 2010.
39. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta 2-glycoprotein autoantibodies. J Thromb Haemost 9: 149-153, 2011.
40. Pengo V. APS-controversies in diagnosis and management, critical overview of current guidelines. Thromb Res 127: S51-S52, 2011.
41. Deng X, Liu X. Reevaluation of predictive value of ACL and anti- 2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world. Rheumatol Int 32: 3881-3886, 2012.
42. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Laura Bertolaccini M. Clinical accuracy for diagnosis of Antiphospholipid Syndrome in SLE: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10: 2512-2518, 2012.
43. Nojima J. Advanced clinical laboratory studies in the graduate school of medicine-studies on pathogenic mechanisms of antiphospholipid syndrome. Rinsho Byori (The Japanese Journal of Clinical Pathology) 57: 786-792, 2009 (in Japanese, Abstract in English).
44. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64: 504-512, 2012.
45. Horvei LD, Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Obesity measures and risk of venous thromboembolism and myocardial infarction. Eur J Epidemiol 29: 821-830, 2014.